FTL008.16, a 5T4-Conditional 4-1BB bispecific antibody, potently enhances antitumor immunity via tumor-directed t-cell activation
Shuang Liu, Ziqing Ren, Yongyan Tu, Pengyu Chen, Yinglu Zhang, Shengyan Zhao, Xiaofeng Chen, Han Deng, Shuyun Yang, Feng Qu, Ming Zhang, Lantu Gou, Qing Li, Ying Huang, Fanxin Ma, Jinliang Yang · 2026
Read FTL008.16, a 5T4-Conditional 4-1BB bispecific antibody, potently enhances antitumor immunity via tumor-directed t-cell activation by Shuang Liu, Ziqing Ren, Yongyan Tu, Pengyu Chen, Yinglu Zhang, Shengyan Zhao, Xiaofeng Chen, Han Deng, Shuyun Yang, Feng Qu, Ming Zhang, Lantu Gou, Qing Li, Ying Huang, Fanxin Ma, Jinliang Yang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13271331.txt.
Description
Shuang Liu is lead author of a 2026 journal article on FTL008.16, a bispecific antibody designed to switch on T cells only inside tumours. Drugs that activate the 4-1BB receptor on T cells can fight cancer but have been limited by liver damage. This antibody also binds 5T4, a protein found on tumour cells, so activation needs both targets.
In cell tests, the antibody boosted T cell growth, signal release, and tumour killing only when 5T4 was present. In two mouse tumour models it beat a standard 4-1BB antibody, fully clearing tumours in one model. In monkeys, even a high dose caused no rise in liver enzymes, suggesting a safer profile.
Catalog record
| CREATOR | Shuang Liu, Ziqing Ren, Yongyan Tu, Pengyu Chen, Yinglu Zhang, Shengyan Zhao, Xiaofeng Chen, Han Deng, Shuyun Yang, Feng Qu, Ming Zhang, Lantu Gou, Qing Li, Ying Huang, Fanxin Ma, Jinliang Yang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 49158 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |